SUNPHARMA:NSE
Sun Pharmaceutical Industries Ltd
₹ 1,758.80
arrow_downward
-0.29%(-5.20) Siku 1
16 Okt, 15:30:00 GMT +5:30 · INR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya SUNPHARMA...
Fungua
₹ 1,762.20
Juu
₹ 1,764.90
Chini
₹ 1,743.50
Mtaji wa soko
4.22T
Wastani wa kiasi cha mauzo
1.45M
Kiasi cha mauzo ya hisa
1.52M
Gawio
0.91%
Mgawo wa faida wa kila robo mwaka
₹ 4.00
Tarehe ya kutojumuisha gawio
7 Jul 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
34.87
Juu kwa wiki 52
₹ 2,046.90
Chini kwa wiki 52
₹ 1,583.70
EPS
₹ 50.44
Hisa za wawekezaji
0.00
Idadi ya wafanyakazi
elfu 47
Fungua
₹ 1,762.20
Juu
₹ 1,764.90
Chini
₹ 1,743.50
Mtaji wa soko
4.22T
Wastani wa kiasi cha mauzo
1.45M
Kiasi cha mauzo ya hisa
1.52M
Gawio
0.91%
Mgawo wa faida wa kila robo mwaka
₹ 4.00
Tarehe ya kutojumuisha gawio
7 Jul 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
34.87
Juu kwa wiki 52
₹ 2,046.90
Chini kwa wiki 52
₹ 1,583.70
EPS
₹ 50.44
Hisa za wawekezaji
0.00
Idadi ya wafanyakazi
elfu 47
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 11 zilizopita
Sun Pharma stock: Results are due October 29 for Sun Pharma stock
ad-hoc-news.de
·
saa 17 zilizopita
Crisil rates Sun Pharma debt AAA. Sun Pharma stock is valued at INR 4.2 trillion
ad-hoc-news.de
·
siku 1 iliyopita
Analyst consensus puts Sun Pharma stock at INR 2,180.00
Moneycontrol.com
·
siku 2 zilizopita
Sun Pharma: Tariff relief, innovation brighten growth outlook
Wasifu
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Kuhusu Sun Pharmaceutical Industries Ltd
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazielfu 47
Lilianzishwa1983
Makao makuuGoregaon East, Mumbai, India
Sekta-
Tovutisunpharma.com